AlphAIAlphAI — Financial news for AI agents
finance.yahoo.comOCT 231 min read$MRNA

ESMO26: MSD and Moderna drop cancer vaccine trial data early

MSD and Moderna released cancer vaccine trial data early due to a leak. The INTerpath-001 trial showed promising results for high-risk melanoma patients. GlobalData predicts sales could exceed $1bn by 2031, according to the company.

Original reporting
finance.yahoo.com
Published Oct 23, 2026, 12:54 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 23, 2026, 1:03 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
ESMO26: MSD and Moderna drop cancer vaccine trial data early — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$MRNABullishHigh
01

Why it matters

Early data release creates a short‑term trading opportunity as markets react to the unexpected timing.

02

Market read

Both MRK and MRNA could experience immediate price moves due to the surprise early trial data.

03

What to watch

Regulatory review timelines and manufacturing capacity could temper upside.

Relevance 7/10Novelty 9/10Timing: early release ahead of conference

Background

The ESMO26 conference was scheduled to release the data on Oct 24, but the information was leaked on Oct 22.

Company-level read

Ticker impact

$MRNABullishHigh confidence
Context

Moderna cancer vaccine trial data was released early, suggesting favorable outcomes.

Expected impact

likely upward pressure as investors price in efficacy expectations

Evidence & confidence

Early disclosure of trial success is a fresh catalyst for a biotech stock.

Market effects

Sector

Could lift the broader oncology biotech sector.

Regional

May boost US biotech indices.

Global

Highlights progress in cancer vaccine development worldwide.

Counterpoint

What could challenge this read

Skeptics may wait for full data before committing, fearing over‑optimism.

Key entities

  • company
    Merck & Co.

    US‑listed pharmaceutical company (ticker MRK).

  • company
    Moderna Inc.

    US‑listed mRNA biotech firm (ticker MRNA).

Read at source← All news

StoryModerna and Merck shares tumble after leak of Phase 3 melanoma vaccine data

Also covered by

6 outlets

Related articles

OCT 23
$MRNAMed

Moderna stock extends decline after leaked data on melanoma vaccine trial

Moderna (MRNA) stock fell 2% on Friday, extending a 17% drop from Thursday, after leaked data from a late-stage melanoma vaccine trial disappointed investors. The trial was conducted with Merck (MRK). Goldman Sachs (GS) raised its target to $137, while Morgan Stanley (MS) and Citi (C) maintain Neutral and Sell ratings, respectively. The stock is down from $200 despite positive Phase 3 results in August.

finance.yahoo.com2 min
OCT 23
$MRNAMed

Moderna Sinks 4% After 18% Plunge as Melanoma Vaccine Selloff Extends; Merck and Pfizer Slip

Moderna (MRNA) shares fell 4% to $193.62, extending an 18% drop, after full late-stage results for its melanoma vaccine with Merck (MRK) were released. The data met expectations but fell short of high hopes, triggering a correction. Moderna's stock is more exposed due to its focus on oncology, while Merck's stock declined 0.8% to $146. Pfizer (PFE) also saw a minor decline of 0.7% to $30.22.

247wallst.com2 min
OCT 23
$MRKMed

Moderna And Merck Cancer Vaccine Cuts Melanoma Death Risk By 42%

Moderna and Merck (MRK) reported that their personalized mRNA cancer vaccine, combined with Merck's Keytruda, reduced melanoma death or recurrence risk by 42% in a Phase 3 trial. The vaccine is expected to launch in 2027 and is also being tested in other cancers. Merck's stock fell 1.8% on the news, while Moderna's stock dropped over 17%. Keytruda sales were $8.4 billion in the latest quarter, up 4%.

finance.yahoo.com3 min
OCT 23
$CCIMed

SpaceX in Talks to Acquire 80,000 Cell Sites, Targeting Fourth US National Carrier; Optical Communications and Memory Stocks Rally in US Pre-Market

SpaceX is in talks to acquire 80,000 cell sites, potentially becoming the fourth US national wireless carrier. Optical communications and memory stocks rose in pre-market trading, with Western Digital reporting strong Q1 earnings. Intel received a one-year FCC exemption, while OpenAI lowered its funding valuation. Moderna shares fell after early data leak of its cancer vaccine trial.

finance.biggo.com4 min